High-dose IFN and PEG IFN for Induction Therapy in Difficult to Treat Genotype 1 Patients With Chronic HCV

NCT ID: NCT00381953

Last Updated: 2021-09-01

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 33 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2003-02-28
• Study Completion Date: 2006-07-31

Brief Summary

Comparison of virological breakthrough/relapse rate after dose adjustments and sustained virological response rate will be assessed by the type of induction.

Detailed Description

The purpose of this study is to compare pharmacokinetics by IFN assays and pharmacodynamics by patient's HCVRNA suppression of 360 mug peginterferon QW, 9 MU interferon daily or 4,5 MU interferon daily in combination with 180 mug peginterferon QW in the first 4 weeks of treatment. Comparison of virological breakthrough/relapse rate after dose adjustments and sustained virological response rate will be assessed by the type of induction.

Conditions

Hepatitis C

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

360 PEG IFN

360 mug peginterferon alfa-2a QW

Group Type: ACTIVE_COMPARATOR

Peginterferon alfa-2a

Intervention Type: DRUG

Ribavirin

Intervention Type: DRUG

9 MU + 180 PEG IFN

9 MU interferon daily in combination with 180 mug peginterferon QW in the first 4 weeks of treatment

Group Type: ACTIVE_COMPARATOR

Peginterferon alfa-2a

Intervention Type: DRUG

Interferon alfa-2a

Intervention Type: DRUG

Ribavirin

Intervention Type: DRUG

4,5 MU IFN + 180 PEG IFN

4,5 MU interferon daily in combination with 180 mug peginterferon QW in the first 4 weeks of treatment

Group Type: ACTIVE_COMPARATOR

Peginterferon alfa-2a

Intervention Type: DRUG

Interferon alfa-2a

Intervention Type: DRUG

Ribavirin

Intervention Type: DRUG

Interventions

Peginterferon alfa-2a

Intervention Type: DRUG

Interferon alfa-2a

Intervention Type: DRUG

Ribavirin

Intervention Type: DRUG

Other Intervention Names

Pegasys; Intron-A; Copegus

Eligibility Criteria

Inclusion Criteria

• chronic hepatitis C
• detectable serum HCV-RNA
• elevated serum ALT activity documented on at least two occasions within the past 12 months, with at least one during the 90 day screening period preceding the initiation of test drug dosing
• liver biopsy findings (during screening or within previous 12 months) consistent with active fibrosis (haemophiliacs are excluded from biopsies)
• compensated liver disease (Child-Pugh Grade A clinical classification)
• negative urine or blood pregnancy test (for women of childbearing potential) documented within the 24-hour period prior to the first dose of study drug
• all fertile males and females receiving ribavirin and their fertile or potentially fertile partners must be advised to use two forms of effective contraception (combined) during treatment and during the 6 months after end of treatment

Exclusion Criteria

• history or other evidence of severe illness, malignancy or any other condition which would make the patient, in the opinion of the investigator, unsuitable for the study
• women with ongoing pregnancy or breast feeding
• therapy with any systemic anti-viral, anti-neoplastic or immunomodulatory treatment (including supraphysiologic doses of steroids and radiation) <3 months prior to the first dose of study drug
• any investigational drug <6 weeks prior to the first dose of study drug positive test at screening for HBsAg, anti-HIV Ab history or other evidence of bleeding from esophageal varices, ascites, or other conditions consistent with decompensated liver disease (Child-Pugh Grade B or C clinical classification)
• Signs or symptoms of hepatocellular carcinoma
• history or other strong evidence of a medical condition associated with chronic liver disease other than HCV (e.g., primary hemochromatosis, autoimmune hepatitis, metabolic liver disease, alcoholic liver disease, toxin exposures
• Hb <7.5 mmol/l in women or <8.6 mmol/l in men at screening
• any patient with an increased baseline risk for anaemia (e.g. thalassemia, spherocytosis, etc) or for whom anaemia would be medically problematic neutrophil count <1500 cells/mm3 or platelet count <80,000 cells/mm3 at screening
• serum creatinine level >1.5 times the upper limit of normal at screening
• history of severe psychiatric disease, especially depression
• history of a severe seizure disorder or current anticonvulsant use
• history of immunologically mediated disease
• history or other evidence of chronic pulmonary disease associated with functional limitation
• history of severe allergies
• history of symptomatic and/or significant cardiovascular disease
• poorly controlled diabetes mellitus
• history of major organ transplantation with an existing functional graft
• hyper- or hypothyroidism
• evidence of severe retinopathy
• evidence of drug abuse (including excessive alcohol consumption within one year before study entry

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Foundation for Liver Research

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Rob J. de Knegt, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Erasmus Medical Center

Locations

Erasmus Medical Center

Rotterdam, , Netherlands

Countries

Netherlands

Other Identifiers

HCV02-01

Identifier Type: -

Identifier Source: org_study_id